| Outcome Measures: |
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, is located in the Reported Adverse Events module., Baseline to study completion up to 33 days | Secondary: Pharmacokinetics: Area Under the Concentration Curve of LY2922470 From Time Zero to 24 Hours [AUC(0-24)], Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18, 24, 48, 96 and 192 hours postdose|Pharmacokinetics: Maximum Concentration (Cmax) of LY2922470, Predose, 0.5, 1.5, 2.5, 4, 6, 12, 18, 24, 48, 96 and 192 hours postdose|Change From Baseline in Blood Glucose Area Under the Effective Concentration Curve From Time Zero to 24 Hours [AUEC(0-24)], Least Squares (LS) mean values were adjusted for baseline, treatment, period, treatment sequence, participant and error., Baseline (predose for Part A and Day -1 time-matched for Part B), 24 hours postdose|Change From Baseline in C-Peptide Area Under the Effective Concentration Curve From Time Zero to 6 Hours [AUEC(0-6)], LS mean values were adjusted for baseline, treatment, period, treatment sequence, participant and error., Baseline (predose for Part A and Day -1 time-matched for Part B), 6 hours postdose
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
|
